Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-08-29
1996-11-19
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514217, 5142222, 5142278, 5142288, 514 315, 514241, 514247, 514256, 514290, 514307, 514311, 514314, 514315, 514316, 514317, 514318, 514318, 514320, 514321, 514322, 514323, 514324, 514326, 514330, 540519, 540524, 544 14, 544 55, 544 60, 544111, 544224, 544233, 544238, 544245, 544338, 544359, 546 79, 546139, 546148, 546149, 546152, 546187, 546189, 546193, 546195, 546196, 546197, 546198, 546200, 546201, 546205, 546207, 546208, 546209, 546210, 546212, 546214, 546226, A61K 31435, A61K 3144, A61K 3154, A61K 31545
Patent
active
055763138
ABSTRACT:
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.
REFERENCES:
patent: 5043268 (1991-08-01), Stock
patent: 5141851 (1992-08-01), Brown et al.
patent: 5238922 (1993-08-01), Graham et al.
patent: 5326773 (1994-07-01), De Solms et al.
patent: 5340828 (1994-08-01), Graham et al.
patent: 5352705 (1994-10-01), Deana et al.
patent: 5362906 (1994-11-01), Anthony et al.
Okolicany et al, Chemical Abstracts, vol. 116 No. 35046, 1991 "Effects of small C-ANF receptor ligands on plasma levels".
Gibbs, J. B. et al., "Selective Inhibition of Farnesyl-Protein Transferase Blocks Ras Processing in Vivo", The Journal of Biological Chemistry, vol. 268, No. 11, pp. 7617-7620 (1993).
Goldstein, J. L. et al., "Nonfarnesylated Tetrapeptide Inhibitors of Protein Farnesyltranferase", The Journal of Biological Chemistry, vol. 266, No. 24 pp. 15575-15578 (1991).
James, G. L. et al., "Benzodiazepine Peptidomimetic BZA-5B Interrupts the MAP Kinase Activation Pathway in H-Ras-transformed Rat-1 Cells, but Not in Untransformed Cells", The Journal of Biological Chemistry, vol. 369, No. 44, pp. 27705-27714 (1994).
James, G. L. et al., "Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells", Science, vol. 260, pp. 1937-1942 (1993).
Kohl, N. E. et al., "Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor", Science, vol. 260, pp. 1934-1937 (1993).
Kohl, N. E. et al., "Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice", Proc. Natl. Acad. Sci. USA, Med. Sciences, vol. 91, pp. 9141-9145 (1994).
Pompliano, D. L., "Steady-State Kinetic Mechanism of Ras Farnesyl:Protein Transferase", Biochemistry, vol. 31, pp. 3800-3807 (1992).
Culberson J. Christopher
Fisher Thorsten E.
Saari Walfred S.
Wai John S.
Covington Raymond
Daniel Mark R.
Ivy C. Warren
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Inhibitors of farnesyl-protein transferase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of farnesyl-protein transferase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of farnesyl-protein transferase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-541148